

SEQUENCE LISTING

<110> MolMed SpA
 <120> Conjugates for the treatment of mesothelioma
 <130> 179/WO/PA
 <150> EP 08008872.7
 <151> 2008-05-13
 <160> 32
 <170> PatentIn version 3.3
 <210> 1
 <211> 13
 <212> PRT
 <213> Artificial sequence
 <220>
 <223> Description of Artificial Sequence: targeting peptide
 <400> 1

Cys Asn Gly Arg Cys Val Ser Gly Cys Ala Gly Arg Cys
 1 5 10

<210> 2
 <211> 6
 <212> PRT
 <213> Artificial sequence
 <220>
 <223> Description of Artificial Sequence: targeting peptide
 <400> 2

Asn Gly Arg Ala His Ala
 1 5

<210> 3
 <211> 5
 <212> PRT
 <213> Artificial sequence
 <220>
 <223> Description of Artificial Sequence: targeting peptide
 <400> 3

Gly Asn Gly Arg Gly
 1 5

<210> 4
 <211> 9
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<400> 4

Cys Val Leu Asn Gly Arg Met Glu Cys
 1 5

<210> 5
 <211> 5
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<400> 5

Cys Asn Gly Arg Cys
 1 5

<210> 6
 <211> 6
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<400> 6

Cys Asn Gly Arg Cys Gly
 1 5

<210> 7
 <211> 5
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<400> 7

Leu Asn Gly Arg Glu
 1 5

<210> 8
 <211> 5
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<400> 8

Tyr Asn Gly Arg Thr
 1 5

<210> 9
 <211> 16
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<400> 9

Leu Gln Cys Ile Cys Thr Gly Asn Gly Arg Gly Glu Trp Lys Cys Glu
 1 5 10 15

<210> 10
 <211> 16
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<400> 10

Leu Gln Cys Ile Ser Thr Gly Asn Gly Arg Gly Glu Trp Lys Cys Glu
 1 5 10 15

<210> 11
 <211> 13
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<400> 11

Cys Ile Cys Thr Gly Asn Gly Arg Gly Glu Trp Lys Cys
 1 5 10

<210> 12

<211> 13
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<400> 12

Cys Ile Ser Thr Gly Asn Gly Arg Gly Glu Trp Lys Cys
 1 5 10

<210> 13
 <211> 16
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<400> 13

Met Arg Cys Thr Cys Val Gly Asn Gly Arg Gly Glu Trp Thr Cys Tyr
 1 5 10 15

<210> 14
 <211> 16
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<400> 14

Met Arg Cys Thr Ser Val Gly Asn Gly Arg Gly Glu Trp Thr Cys Tyr
 1 5 10 15

<210> 15
 <211> 13
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<400> 15

Cys Thr Cys Val Gly Asn Gly Arg Gly Glu Trp Thr Cys
 1 5 10

<210> 16
 <211> 13

<212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide
 <400> 16

Cys Thr Ser Val Gly Asn Gly Arg Gly Glu Trp Thr Cys
 1 5 10

<210> 17
 <211> 13
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Xaa is isoaspartic acid

<400> 17

Cys Xaa Gly Arg Cys Val Ser Gly Cys Ala Gly Arg Cys
 1 5 10

<210> 18
 <211> 6
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> Xaa is iso-aspartic acid (isoD)

<400> 18

Xaa Gly Arg Ala His Ala
 1 5

<210> 19
 <211> 5
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Xaa is iso-aspartic acid (isoD)

<400> 19

Gly Xaa Gly Arg Gly
 1 5

<210> 20
 <211> 9
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<220>
 <221> MOD_RES
 <222> (4)..(4)
 <223> Xaa is iso-aspartic acid (isoD)

<400> 20

Cys Val Leu Xaa Gly Arg Met Glu Cys
 1 5

<210> 21
 <211> 5
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Xaa is iso-aspartic acid (isoD)

<400> 21

Cys Xaa Gly Arg Cys
 1 5

<210> 22
 <211> 6

<212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Xaa is iso-aspartic acid (isoD)

<400> 22

Cys Xaa Gly Arg Cys Gly
 1 5

<210> 23
 <211> 5
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Xaa is iso-aspartic acid (isoD)

<400> 23

Leu Xaa Gly Arg Glu
 1 5

<210> 24
 <211> 5
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Xaa is iso-aspartic acid (isoD)

<400> 24

Tyr Xaa Gly Arg Thr
 1 5

<210> 25
 <211> 16
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<220>
 <221> MOD_RES
 <222> (8)..(8)
 <223> Xaa is iso-aspartic acid (isoD)

<400> 25

Leu Gln Cys Ile cys Thr Gly xaa Gly Arg Gly Glu Trp Lys Cys Glu
 1 5 10 15

<210> 26
 <211> 16
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<220>
 <221> MOD_RES
 <222> (8)..(8)
 <223> Xaa is iso-aspartic acid (isoD)

<400> 26

Leu Gln Cys Ile Ser Thr Gly xaa Gly Arg Gly Glu Trp Lys Cys Glu
 1 5 10 15

<210> 27
 <211> 13
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: targeting peptide

<220>
 <221> MOD_RES
 <222> (6)..(6)
 <223> Xaa is iso-aspartic acid (isoD)

<400> 27

Cys Ile Cys Thr Gly Xaa Gly Arg Gly Glu Trp Lys Cys
1 5 9 10

<210> 28
<211> 13
<212> PRT
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: targeting peptide

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Xaa is iso-aspartic acid (isoD)

<400> 28

Cys Ile Ser Thr Gly Xaa Gly Arg Gly Glu Trp Lys Cys
1 5 10

<210> 29
<211> 16
<212> PRT
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: targeting peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Xaa is iso-aspartic acid (isoD)

<400> 29

Met Arg Cys Thr Cys Val Gly Xaa Gly Arg Gly Glu Trp Thr Cys Tyr
1 5 10 15

<210> 30
<211> 16
<212> PRT
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: targeting peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Xaa is iso-aspartic acid (isoD)

<400> 30

Met Arg Cys Thr Ser Val Gly Xaa Gly Arg Gly Glu Trp Thr Cys Tyr
 1 5 10 15

<210> 31

<211> 13

<212> PRT

<213> Artificial sequence

<220>

<223> Description of Artificial Sequence: targeting peptide

<220>

<221> MOD_RES

<222> (6)..(6)

<223> Xaa is iso-aspartic acid (isoD)

<400> 31

Cys Thr Cys Val Gly Xaa Gly Arg Gly Glu Trp Thr Cys
 1 5 10

<210> 32

<211> 13

<212> PRT

<213> Artificial sequence

<220>

<223> Description of Artificial Sequence: targeting peptide

<220>

<221> MOD_RES

<222> (6)..(6)

<223> Xaa is iso-aspartic acid (isoD)

<400> 32

Cys Thr Ser Val Gly Xaa Gly Arg Gly Glu Trp Thr Cys
 1 5 10